#United States #Staten Island #Acurx Pharmaceuticals #Antibiotic Development #DNA Polymerase IIIC

Acurx Pharmaceuticals Strengthens Its Patent Portfolio

Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP), a biopharmaceutical company specializing in the development of small molecule antibiotics, has successfully received a new patent from the Korean Intellectual Property Office (KIPO) for its innovative DNA Polymerase IIIC inhibitors. This recent patent safeguards various aspects including compositions of matter and pharmaceutical compositions, augmenting the company’s intellectual property landscape significantly. This is an essential step as Acurx continues to advance its mission to tackle difficult-to-treat bacterial infections that currently pose significant health challenges.

To date, Acurx has already secured four patents in the United States, along with international patents granted in countries such as Israel, Japan, India, Australia, and now Korea. This robust patent protection reflects the company’s dedication to ensuring the exclusivity of its groundbreaking ACX-375C program, which is focused on inhibiting the DNA Polymerase IIIC enzyme, a key player in bacterial DNA replication.

Robert J. DeLuccia, the Executive Chairman of Acurx Pharmaceuticals, expressed enthusiasm regarding the new patent, stating that it extends their patent coverage as they delve deeper into developing an AI-supported drug discovery platform. He emphasizes the potential of their preclinical pipeline, which is filled with promising compounds aimed at revolutionizing the treatment of serious bacterial infections. These infections include Acute Bacterial Skin and Skin Structure Infections (ABSSSI), Community-acquired Bacterial Pneumonia (CABP), and even more severe cases such as bacteremia and inhalational anthrax, highlighting the gravity of healthcare demands they seek to address.

Among its lead compounds, Acurx is gearing up for international Phase 3 trials in the U.S. and EU for ibezapolstat, specifically targeting acute Clostridium difficile infections. This compound, which also shows promise in a groundbreaking trial for patients suffering from recurrent CDI, has the potential to streamline treatment regimens from using multiple agents to a more efficient single-agent protocol. This change could greatly simplify treatment plans for patients, indicating a significant shift in therapeutic approaches.

A Future-Focused on Innovation

With a steadfast focus on developing a new generation of antibiotics, Acurx Pharmaceuticals is not just responding to existing health crises; it is anticipating future challenges in antibiotic-resistant bacteria. Their unique approach aims at Gram-positive selective spectra (GPSS®), targeting specific bacterial strains, including the notorious MRSA and other resistant bacteria.

They are also currently working on developing an oral antibiotic specifically for treating ABSSSI, alongside a parallel development for an inhaled anthrax treatment. The investments and innovations made by Acurx Pharmaceuticals embody a commitment to tackling the pressing issue of antibiotic resistance, relying on advanced scientific research and strong patent protection to carve a niche in the pharmaceutical landscape.

The implication of this new patent extends far beyond Acurx’s internal portfolio; it signals a hopeful future in the biopharmaceutical industry where innovation meets practicality. As Acurx Pharmaceuticals progresses with its trials and develops its antibiotic candidates, the global healthcare community will be closely observing its advancements and the potential impact on treating formidable bacterial infections.

For more insights into Acurx Pharmaceuticals and its innovative product lineup, you can visit their official website at www.acurxpharma.com.